A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

10 Key Vulnerabilities in the Global Pharmaceutical Supply Chain

The global pharmaceutical supply chain, while essential for modern commerce and interconnected economies, is riddled with vulnerabilities that can disrupt the flow of goods and services, leading to economic instability and potential crises. These vulnerabilities have been highlighted by various events in recent years, such as the COVID-19 pandemic and cyberattacks on critical infrastructure. Here are 10 key vulnerabilities of the global supply chain:

  1. Dependency on Single Sources: Many supply chains heavily rely on a single source or a small number of suppliers for critical components or materials. This concentration puts the entire supply chain at risk if that source experiences disruptions due to natural disasters, geopolitical tensions, labor strikes, or other unforeseen events. Diversification of suppliers is crucial to mitigate this vulnerability.
  2. Just-In-Time Inventory: The just-in-time (JIT) inventory strategy, designed to minimize inventory carrying costs, leaves little buffer for disruptions. This means that any interruption in the production or transportation process can quickly lead to shortages and delays, as seen during the early stages of the COVID-19 pandemic when demand for certain products far exceeded supply. More currently, the recent actions taken by the US FDA regarding cisplatin also reflect this vulnerability.
  3. Complexity and Lack of Transparency: Modern supply chains are intricate networks spanning multiple countries and involving various intermediaries. This complexity can lead to a lack of transparency, making it difficult to identify weak points or potential risks. Without a clear view of the entire supply chain, it’s challenging to respond effectively to disruptions.
  4. Geopolitical Factors: Political tensions, trade disputes, and changing regulations between countries can impact the smooth movement of goods across borders. Geopolitical events can lead to sudden trade restrictions, tariffs, or embargoes, disrupting established supply chain routes and relationships.
  5. Cybersecurity Threats and other Criminal Activity: As supply chains become more digitized and interconnected, they become susceptible to cyberattacks. Hackers targeting critical nodes, such as logistics and communication systems, can bring the entire supply chain to a halt. This was demonstrated by the 2017 NotPetya ransomware attack, which disrupted shipping, manufacturing, and logistics operations globally. In the physical world, the prevalence of substandard and falsified medicines around the world indicates that the threat posed by criminal activity in this space requires a concerted effort to defeat it.
  6. Natural Disasters and Climate Change: Extreme weather events, earthquakes, and other natural disasters can disrupt transportation, damage infrastructure, and lead to supply chain interruptions. With the increasing frequency and intensity of these events due to climate change, supply chains are facing higher risks.
  7. Labor Issues: Labor disputes, strikes, and worker shortages can impact various points along the supply chain. From production facilities to transportation hubs, disruptions in labor availability can lead to delays and increased costs.
  8. Infrastructure Vulnerabilities: The infrastructure that supports supply chains, including ports, roads, railways, and communication networks, can be susceptible to physical damage or technological failures. Disruptions in infrastructure can lead to delays in transporting goods and components.
  9. Economic Shocks: Economic downturns can lead to reduced consumer demand, affecting the entire supply chain. Companies may cut back on production, leading to reduced orders for suppliers and subsequently impacting their ability to meet their obligations further down the chain.
  10. Pandemics and Health Crises: The COVID-19 pandemic exposed the vulnerabilities of the global supply chain in unprecedented ways. Travel restrictions, factory closures, and labor shortages significantly disrupted the movement of goods and strained healthcare supply chains.

Science and technology come together to tackle these vulnerabilities

Taken together these factors create conditions in which the potential for substandard and falsified drugs to enter the supply chain increases, placing a premium on the ability to conduct drug quality control in the Pharma supply chain at different stages. The need for statistically driven destructive analyses and timely reporting to stakeholders in the supply chain has never been clearer. ARTiFACTS Verify offers an integrated approach to identifying substandard and falsified drugs:

  • Identification of suspect medicines through on-site testing at any point in the supply chain using paper analytical device technology that is cost-effective and requires minimal training.
  • Confirmation of the properties of medicines failing the initial test through further testing at specialist labs, using advanced scientifically recognized techniques, including high-performance liquid chromatography, mass spectroscopy, among others.
  • Coverage of over half of WHO’s 600 Essential Medicines.
  • Recording and analysis of results on a purpose-built blockchain platform which provides an immutable record of test results, including active pharmaceutical ingredients, product origin and manufacturer.

By focusing on medicines that have found their way into the supply chain, Verify satisfies the pressing need for a service capable of identifying suspect drugs before they reach patients even if they have eluded detection in the manufacturing process.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy